Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ICLR's Cash to Debt is ranked higher than
95% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. ICLR: No Debt )
ICLR' s 10-Year Cash to Debt Range
Min: 0.85   Max: No Debt
Current: No Debt

Equity to Asset 0.64
ICLR's Equity to Asset is ranked higher than
73% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. ICLR: 0.64 )
ICLR' s 10-Year Equity to Asset Range
Min: 0.53   Max: 0.77
Current: 0.64

0.53
0.77
Interest Coverage 94.07
ICLR's Interest Coverage is ranked higher than
68% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.07 vs. ICLR: 94.07 )
ICLR' s 10-Year Interest Coverage Range
Min: 17.93   Max: 9999.99
Current: 94.07

17.93
9999.99
F-Score: 6
Z-Score: 5.68
M-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 12.99
ICLR's Operating margin (%) is ranked higher than
90% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. ICLR: 12.99 )
ICLR' s 10-Year Operating margin (%) Range
Min: 3.11   Max: 12.11
Current: 12.99

3.11
12.11
Net-margin (%) 11.02
ICLR's Net-margin (%) is ranked higher than
91% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. ICLR: 11.02 )
ICLR' s 10-Year Net-margin (%) Range
Min: 2.42   Max: 13.44
Current: 11.02

2.42
13.44
ROE (%) 16.98
ICLR's ROE (%) is ranked higher than
91% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. ICLR: 16.98 )
ICLR' s 10-Year ROE (%) Range
Min: 3.39   Max: 22.48
Current: 16.98

3.39
22.48
ROA (%) 10.88
ICLR's ROA (%) is ranked higher than
93% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. ICLR: 10.88 )
ICLR' s 10-Year ROA (%) Range
Min: 2.31   Max: 16.82
Current: 10.88

2.31
16.82
ROC (Joel Greenblatt) (%) 82.49
ICLR's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. ICLR: 82.49 )
ICLR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 11.96   Max: 57.6
Current: 82.49

11.96
57.6
Revenue Growth (3Y)(%) 13.10
ICLR's Revenue Growth (3Y)(%) is ranked higher than
92% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. ICLR: 13.10 )
ICLR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -14.6   Max: 54.5
Current: 13.1

-14.6
54.5
EBITDA Growth (3Y)(%) 8.70
ICLR's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ICLR: 8.70 )
ICLR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 36.6
Current: 8.7

0
36.6
EPS Growth (3Y)(%) 4.60
ICLR's EPS Growth (3Y)(%) is ranked higher than
78% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. ICLR: 4.60 )
ICLR' s 10-Year EPS Growth (3Y)(%) Range
Min: -34.2   Max: 54.4
Current: 4.6

-34.2
54.4
» ICLR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ICLR Guru Trades in Q4 2013

Paul Tudor Jones 200,000 sh (New)
Steven Cohen 219,406 sh (+2329.48%)
Jim Simons 830,860 sh (+67.8%)
Ron Baron 1,430,000 sh (+11.72%)
RS Investment Management 500,960 sh (+6.51%)
Chuck Royce 210,200 sh (unchged)
Jean-Marie Eveillard 12,000 sh (unchged)
» More
Q1 2014

ICLR Guru Trades in Q1 2014

Caxton Associates 15,000 sh (New)
Chuck Royce 210,200 sh (unchged)
Ron Baron 1,430,000 sh (unchged)
Jean-Marie Eveillard 12,000 sh (unchged)
Paul Tudor Jones Sold Out
RS Investment Management Sold Out
Steven Cohen 195,389 sh (-10.95%)
Jim Simons 712,260 sh (-14.27%)
» More
Q2 2014

ICLR Guru Trades in Q2 2014

Ron Baron 1,530,000 sh (+6.99%)
Chuck Royce 210,200 sh (unchged)
Caxton Associates Sold Out
Jean-Marie Eveillard Sold Out
Jim Simons 613,600 sh (-13.85%)
» More
Q3 2014

ICLR Guru Trades in Q3 2014

Caxton Associates 50,000 sh (New)
Jim Simons 690,100 sh (+12.47%)
Chuck Royce 210,200 sh (unchged)
Ron Baron 1,515,624 sh (-0.94%)
» More
» Details

Insider Trades

Latest Guru Trades with ICLR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-06-30 Sold Out $37.92 - $48.97 $ 52.8122%0
Ron Baron 2013-09-30 Add 25.15%0.05%$36.24 - $40.67 $ 52.8137%1280000
Ron Baron 2013-06-30 Add 24.31%0.04%$29.2 - $36.22 $ 52.8160%1022800
Meridian Funds 2013-03-31 Reduce -33.19%0.17%$27.25 - $32.91 $ 52.8177%308000
Ron Baron 2013-03-31 New Buy0.15%$27.25 - $32.91 $ 52.8177%822800
Meridian Funds 2012-12-31 Reduce -28.22%0.16%$23.46 - $28.54 $ 52.81100%461000
Meridian Funds 2012-06-30 Add 24.87%0.1%$20.51 - $23.23 $ 52.81142%642200
Meridian Funds 2012-03-31 Add 25.16%0.06%$17.06 - $22.01 $ 52.81178%514300
Jean-Marie Eveillard 2011-09-30 Add 36.36%$16.5 - $25.21 $ 52.81156%15000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Icon PLC

Meridian Funds Comments on Icon PLC - Dec 17, 2014

ICON (ICLR) manages clinical trials for the biotech, pharmaceutical and medical device industries. Our investment in the company materialized when earnings were pressured by an industry slowdown in clinical trials at the same time that ICON was investing in its own capacity expansion. We viewed the slowdown in demand as temporary, caused by the elimination of many duplicative drug development programs. In addition, we thought ICON’s investments in technology positioned the company to gain market share in a growing industry as pharmaceutical customers increasingly outsourced clinical trial work. Strong stock performance in the quarter was driven by revenue and margins coming in above street estimates and a positive management outlook. We continue to hold shares in ICON based on its positioning as a technology leader in the clinical trial industry and the potential to further expand operating margins

From Meridian Funds (Trades, Portfolio)’ Meridian Contrarian Fund 3Q 2014 Commentary.

Check out Meridian Funds latest stock trades

Baron Funds Comments on ICON PLC - Jun 10, 2013

Other purchases in the quarter include ICON plc (ICLR), which is a CRO (Contract Research Organization) providing outsourced drug research to the pharmaceutical industry. We observed from our investment in Covance that the industry is turning, so we purchased a stake in ICON to increase the Fund's exposure to the trend.

From Baron Funds’ first quarter 2013 commentary.
Check out Ron Baron latest stock trades

Top Ranked Articles about Icon PLC

Meridian Funds Comments on Icon PLC
ICON (ICLR) manages clinical trials for the biotech, pharmaceutical and medical device industries. Our investment in the company materialized when earnings were pressured by an industry slowdown in clinical trials at the same time that ICON was investing in its own capacity expansion. We viewed the slowdown in demand as temporary, caused by the elimination of many duplicative drug development programs. In addition, we thought ICON’s investments in technology positioned the company to gain market share in a growing industry as pharmaceutical customers increasingly outsourced clinical trial work. Strong stock performance in the quarter was driven by revenue and margins coming in above street estimates and a positive management outlook. We continue to hold shares in ICON based on its positioning as a technology leader in the clinical trial industry and the potential to further expand operating margins Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.90
ICLR's P/E(ttm) is ranked higher than
93% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 20.90 )
ICLR' s 10-Year P/E(ttm) Range
Min: 4.37   Max: 78.79
Current: 20.9

4.37
78.79
P/B 3.22
ICLR's P/B is ranked higher than
77% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. ICLR: 3.22 )
ICLR' s 10-Year P/B Range
Min: 0.46   Max: 5.55
Current: 3.22

0.46
5.55
P/S 2.29
ICLR's P/S is ranked higher than
78% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.17 vs. ICLR: 2.29 )
ICLR' s 10-Year P/S Range
Min: 0.58   Max: 2.52
Current: 2.29

0.58
2.52
PFCF 20.39
ICLR's PFCF is ranked higher than
92% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 20.39 )
ICLR' s 10-Year PFCF Range
Min: 5.14   Max: 600.13
Current: 20.39

5.14
600.13
EV-to-EBIT 15.85
ICLR's EV-to-EBIT is ranked higher than
90% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 15.85 )
ICLR' s 10-Year EV-to-EBIT Range
Min: -10.1   Max: 50.5
Current: 15.85

-10.1
50.5
PEG 13.06
ICLR's PEG is ranked higher than
87% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 13.06 )
ICLR' s 10-Year PEG Range
Min: 0.08   Max: 11.49
Current: 13.06

0.08
11.49
Shiller P/E 36.55
ICLR's Shiller P/E is ranked higher than
91% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 36.55 )
ICLR' s 10-Year Shiller P/E Range
Min: 6.42   Max: 40.33
Current: 36.55

6.42
40.33
Current Ratio 1.60
ICLR's Current Ratio is ranked higher than
60% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. ICLR: 1.60 )
ICLR' s 10-Year Current Ratio Range
Min: 1.48   Max: 3.61
Current: 1.6

1.48
3.61
Quick Ratio 1.60
ICLR's Quick Ratio is ranked higher than
62% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. ICLR: 1.60 )
ICLR' s 10-Year Quick Ratio Range
Min: 1.48   Max: 3.61
Current: 1.6

1.48
3.61

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.67
ICLR's Price/Tangible Book is ranked higher than
74% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.25 vs. ICLR: 6.67 )
ICLR' s 10-Year Price/Tangible Book Range
Min: 0.64   Max: 7.26
Current: 6.67

0.64
7.26
Price/DCF (Projected) 1.59
ICLR's Price/DCF (Projected) is ranked higher than
92% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 1.59 )
ICLR' s 10-Year Price/DCF (Projected) Range
Min: 0.52   Max: 6.7
Current: 1.59

0.52
6.7
Price/Median PS Value 1.62
ICLR's Price/Median PS Value is ranked higher than
66% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. ICLR: 1.62 )
ICLR' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 1.76
Current: 1.62

0.4
1.76
Price/Peter Lynch Fair Value 2.35
ICLR's Price/Peter Lynch Fair Value is ranked higher than
93% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 2.35 )
ICLR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.2   Max: 3.15
Current: 2.35

0.2
3.15
Price/Graham Number 2.45
ICLR's Price/Graham Number is ranked higher than
88% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 2.45 )
ICLR' s 10-Year Price/Graham Number Range
Min: 0.41   Max: 3.59
Current: 2.45

0.41
3.59
Earnings Yield (Greenblatt) 6.30
ICLR's Earnings Yield (Greenblatt) is ranked higher than
90% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. ICLR: 6.30 )
ICLR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2   Max: 71.7
Current: 6.3

2
71.7
Forward Rate of Return (Yacktman) 11.57
ICLR's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.28 vs. ICLR: 11.57 )
ICLR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -15.7   Max: 55.6
Current: 11.57

-15.7
55.6

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:0NBW.UK,
Icon PLC was incorporated in 1990. The Company is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The Company organized, operated and assessed its business in two segments, the clinical research segment and the central laboratory segment. The Clinical Research business specializes in the planning, management, execution and analysis of Phase I - IV clinical trials, ranging from small studies to complex, multinational projects. It also conduct various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial Specific clinical research services. The Company provides laboratory services through its central laboratory business, which includes the Company's central laboratories located in Dublin, New York, India, Singapore and China. The Company's areas of operation outside of Ireland include the United States, United Kingdom, France, Germany, Italy, Spain, The Netherlands, Sweden, Belgium, Turkey, Poland, Czech Republic, Lithuania, Latvia, Russia, Ukraine, Hungary, Israel, Romania, Canada, Mexico, Brazil, Colombia, Argentina, Chile, Peru, India, China, South Korea, Japan, Thailand, Taiwan, Singapore, The Philippines, Australia, New Zealand, and South Africa. The Company's principal competitors are Covance Inc., PAREXEL International Corporation, Pharmaceutical Product Development Inc., Quintiles Transnational Corporation, inVentiv Health , PRA and INC Research.
» More Articles for ICLR

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Icon PLC Dec 17 2014 
Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
Baron Funds Comments on ICON PLC Jun 10 2013 
Parexcel: Great Growth but a Tough Business Aug 17 2011 
Weekly Guru Bargains Highlights: SD, CREE, AMLN, ICLR, CVD Nov 07 2010 
ICON publie ses orientations financières pour l’année 2009 et les mises à jour des orientations Jan 09 2009 
Resumen: ICON presenta previsiones financieras para 2009 y actualiza las de 2008 Jan 09 2009 
Samenvatting: ICON publiceert cijfers voor 2009 en werkt cijfers 2008 bij Jan 09 2009 
ICON veröffentlicht Ergebniserwartung für 2009 und aktualisiert Erwartung für 2008 (NASDAQ:ICLR) Jan 09 2009 
ICON Issues Financial Guidance for 2009 and Updates Guidance for 2008 (NASDAQ:ICLR) (ISIN:IE00057112 Jan 09 2009 


More From Other Websites
Cancer Genetics (CGIX) Looks Good: Stock Rises 8% Dec 11 2014
Five Growth Standout Stocks To Buy Nov 28 2014
BioTelemetry (BEAT) Catches Eye: Stock Jumps 5.7% Nov 28 2014
Will Higher Expenses Hurt Intrexon (XON) Earnings in Q3? Nov 12 2014
Intrexon (XON) Looks Good: Stock Moves 11% Higher Nov 12 2014
ICON Selected by the FDA to Develop New Patient-Reported Outcome Measure for Hospital-Acquired... Nov 06 2014
ICON Selected by the FDA to Develop New Patient-Reported Outcome Measure for Hospital-Acquired... Nov 06 2014
Strength Seen in Covance (CVD): Stock Surges 25.9% Nov 04 2014
S&P 500 trades in a narrow range, up against key technical levels Oct 27 2014
ICON plc downgraded by Barclays Oct 27 2014
Omnicare Beats on Q3 Earnings and Sales, Outlook Positive Oct 27 2014
ICON PLC Earnings Call scheduled for 9:00 am ET today Oct 22 2014
Q3 2014 ICON PLC Earnings Release - Time Not Supplied Oct 22 2014
ICON Reports Third Quarter 2014 and Increases Earnings Guidance Oct 22 2014
ICON Reports Third Quarter 2014 and Increases Earnings Guidance Oct 22 2014
Is a Surprise Coming for ICON Public Limited (ICLR) This Earnings Season? Oct 20 2014
Why the Earnings Streak Will Continue for ICON Public Limited (ICLR) Sep 23 2014
ICON Plc Announces Completion of $40 Million Share Buyback and a Further Share Buyback Program for... Sep 19 2014
ICON Plc Announces Completion of $40 Million Share Buyback and a Further Share Buyback Program for... Sep 19 2014
Taking Stock: Baird’s Skorney on Developing ‘Hot Drug’ Sep 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK